Nurix Therapeutics, Inc. 10-Q

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds Use of Proceeds On July 23, 2020, our registration statement on Form S-1, as amended (File No. 333-239651), was declared effective by the SEC in connection with the IPO of our common stock. There has been no material change in the planned use of proceeds from our IPO as described in the prospectus filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act on July 24, 2020. Unregistered Sales of Equity Securities None. Purchases of Equity Securities by Issuers and Affiliated Purchasers The table below provides information with respect to recent repurchases of unvested shares of our common stock: Period Total Number of Shares Purchased ( 1) Average Price Paid per Share Total Number of Shares Purchased as part of Publicly Announced Plans or Programs Maximum Number of Shares that May Yet Be Purchased Under the Plans or Program December 1 – December 31, 2020 — — — — January 1 – January 31, 2021 971 $1.20 — — February 1 – February 28, 2021 — — — — (1) All of the shares repurchased, as reflected in the table above, were repurchases of unvested shares of our common stock that had been issued upon early exercise of stock options. Upon termination of employment of a person holding unvested shares, we are entitled to repurchase the unvested shares. Item 3. Defaults Upon Senior Securities None. Item 4. Mine Safety Disclosures None.